ANGPT2 and central nervous system cancer: Therefore, to increase the benefit from antiangiogenic treatment strategies in glioma, it appears necessary to test these two possibilities: by directly comparing how inhibitors of VEGF-A, Ang-2, and both affect multiple critical parameters of tumor biology, and, most importantly, whether that benefits concomitant chemotherapy, radiotherapy, or both.